|NCPE Assessment Process Complete
|Treatment of adult patients with relapsed or refractory CD30 positive Hodgkin lymphoma following autologous stem cell transplant or following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option and is also indicated for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma.
|Rapid review commissioned
|Rapid review completed
|Rapid review outcome
|Full Pharmacoeconomic Assessment Recommended
|Full submission received from Applicant
|NCPE assessment completed
|NCPE assessment outcome
|Reimbursement not Recommended
The HSE has approved reimbursement following confidential price negotiations.